Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The clinical diagnosis of Parkinson's disease (PD) is established through clinical signs such as bradykinesia, rigidity, and resting tremor. Recently, immune system involvement has been implicated as a major pathogenic factor in the onset and progression of PD. We examine the presence of autoantibodies against phosphatidylserine (PS), cardiolipin (CL) and dsDNA in 45 PD patients and 38 healthy controls and provide evidence to the possible connection to oxidative stress. We report higher frequency of IgG anti-PS and anti-dsDNA in PD patients (24.4% and 15.6%), compared to controls (2.6% in both cases, p < 0.05). Moreover, the presence of these autoantibodies is not analogous with increased levels of oxidative stress in PD. A great need exists for improved understanding of the pathogenesis and identification of relevant biomarkers and future studies in clarifying the role of autoantibodies in PD are required to address its role as a potential risk factor.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jocn.2018.06.004 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!